The estimated Net Worth of James V Cassella is at least $3.61 Milione dollars as of 15 February 2023. James Cassella owns over 3,762 units of Concert Pharmaceuticals Inc stock worth over $1,448,521 and over the last 10 years he sold CNCE stock worth over $470,354. In addition, he makes $1,695,040 as Chief Development Officer at Concert Pharmaceuticals Inc.
Sign up
James Cassella CNCE stock SEC Form 4 insiders trading
James has made over 9 trades of the Concert Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 3,762 units of CNCE stock worth $31,375 on 15 February 2023.
The largest trade he's ever made was selling 10,582 units of Concert Pharmaceuticals Inc stock on 17 April 2018 worth over $213,545. On average, James trades about 1,793 units every 63 days since 2015. As of 15 February 2023 he still owns at least 173,061 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of James Cassella stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Cassella biography
Dr. James V. Cassella Ph.D. serves as Chief Development Officer of the Company. He has served as our Chief Development Officer since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc., a biotechnology company, from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from 2004 to July 2012. From 1989 to 2004, Dr. Cassella held various management positions at Neurogen Corporation, a biotechnology company. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a B.A. in Psychology from the University of New Haven and a Ph.D. in Physiological Psychology from Dartmouth College and completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine.
What is the salary of James Cassella?
As the Chief Development Officer of Concert Pharmaceuticals Inc, the total compensation of James Cassella at Concert Pharmaceuticals Inc is $1,695,040. There are 3 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of $2,772,350.
How old is James Cassella?
James Cassella is 65, he's been the Chief Development Officer of Concert Pharmaceuticals Inc since 2015. There are 3 older and 12 younger executives at Concert Pharmaceuticals Inc. The oldest executive at Concert Pharmaceuticals Inc is Peter Hutt, 85, who is the Independent Director.
What's James Cassella's mailing address?
James's mailing address filed with the SEC is C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510.
Insiders trading at Concert Pharmaceuticals Inc
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... e Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.
What does Concert Pharmaceuticals Inc do?
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
What does Concert Pharmaceuticals Inc's logo look like?
Complete history of James Cassella stock trades at Concert Pharmaceuticals Inc e Trevi Therapeutics
Concert Pharmaceuticals Inc executives and stock owners
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Roger Tung,
President, Chief Executive Officer, Co-Founder, Director -
Nancy Stuart,
Chief Operating Officer -
Marc Becker,
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer -
James Cassella,
Chief Development Officer -
Dr. Roger D. Tung,
Co-Founder, CEO, Pres & Exec. Director -
Dr. James V. Cassella,
Chief Devel. Officer -
Jesper Hoiland,
Independent Director -
Richard Aldrich,
Independent Chairman of the Board, Co-Founder -
Thomas Auchincloss,
Independent Director -
Ronald Barrett,
Independent Director -
Peter Hutt,
Independent Director -
Christine van Heek,
Independent Director -
Wilfred Jaeger,
Independent Director -
Richard H. Aldrich M.B.A., Mba,
Co-Founder & Chairman -
Justine Koenigsberg,
Senior Vice President, Corporate Communications and Investor Relations -
Jeffrey Munsie,
Chief Legal Officer, Secretary -
Christine Boisclair,
Sr. VP of Regulatory Affairs & Quality Assurance -
Dr. Nabil Uddin Pharm.D.,
VP of Corp. Devel. -
Jeffrey A. Munsie,
Chief Legal Officer & Corp. Sec. -
Marc A. Becker,
CFO & Principal Accounting Officer -
Nancy Stuart,
Chief Operating Officer -
Wendall Wierenga,
Director -
Wilfred Ethree Arch Managem...,
-
Pauline Mc Gowan,
VP, Finance -
D. Ryan Daws,
Chief Financial Officer -
Robert Silverman,
Senior VP, General Counsel -
Meghan Fitzgerald,
Director -
Lynette Herscha,
General Counsel -
Heek Christi Van,
Director -
Ryan Lynch,
PAO -
Partners L P/Ilbiotechnolog...,
-
Leaf Ventures I, L.P.New Le...,
-
Helmut Schuhsler,
Director -
John Gordon Freund,
Director -
Associates Gp Llcqvt Fund V...,
-
Capital Management Llcbrook...,
-
Ventures Fund 2004 L P Flag...,
-
Plc Gsk,
-
Capital Partners, L.P.Adage...,
-
Venture Partners Qualified ...,
-
Life Science Ventures Vi Gm...,
-
Arch Management Iv, L.L.C.J...,
-
Arch Management Iii Llcthre...,
-
Arch Management Iv, L.L.C.J...,
-
Xii Gp Llc Greylock Xii Lim...,
-
Arch Management Iii Llcjaeg...,
-
Jesper Hoeiland,
Director -
Marc A. Becker,
Chief Financial Officer